finance

Why major insulin makers are now slashing prices – and why one is still a holdout


Will Sanofi follow the lead of Eli Lily and Novo Nordisk in slashing the price of insulin? Here’s why it’s been so expensive and what’s next.

     



READ SOURCE

Readers Also Like:  ‘There are no domestic equity investors’: why companies are fleeing London’s stock market

This website uses cookies. By continuing to use this site, you accept our use of cookies.